These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38482096)

  • 1. Reactive Arthritis After mpox Vaccination.
    Acharya I; Smith LW; Banerjee C; Camire LM; Vij R
    J Community Hosp Intern Med Perspect; 2024; 14(1):35-38. PubMed ID: 38482096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database.
    Geier DA; Geier MR
    Clin Exp Rheumatol; 2002; 20(6):767-71. PubMed ID: 12508767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).
    Shimabukuro TT; Nguyen M; Martin D; DeStefano F
    Vaccine; 2015 Aug; 33(36):4398-405. PubMed ID: 26209838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
    Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
    Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone?
    Haber P; Chen RT; Zanardi LR; Mootrey GT; English R; Braun MM;
    Pediatrics; 2004 Apr; 113(4):e353-9. PubMed ID: 15060267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of vaccine perception and vaccination intention of Mpox infection among the adult males in Bangladesh: A cross-sectional study findings.
    Islam MR; Haque MA; Ahamed B; Tanbir M; Khan MR; Eqbal S; Rahman MA; Shahriar M; Bhuiyan MA
    PLoS One; 2023; 18(6):e0286322. PubMed ID: 37289746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress Toward Equitable Mpox Vaccination Coverage: A Shortfall Analysis - United States, May 2022-April 2023.
    Kota KK; Chesson H; Hong J; Zelaya C; Spicknall IH; Riser AP; Hurley E; Currie DW; Lash RR; Carnes N; Concepción-Acevedo J; Ellington S; Belay ED; Mermin J
    MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(23):627-632. PubMed ID: 37289660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research progress on the effectiveness of smallpox vaccination against mpox virus infection].
    Xu YS; Jiang MY; Cao YL; Sun YX; Huang QR; Yang WZ; Feng LZ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Apr; 44(4):673-676. PubMed ID: 37147844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mpox Case Reports in an Urban Homeless Population and a Proof of Concept for a Street-Based Mobile Mpox Vaccination Clinic.
    Zeien J; Vieira J; Hanna J; Surendra L; Stenzel J; Ramirez A; Miller C; Rosales C
    J Prim Care Community Health; 2023; 14():21501319231169991. PubMed ID: 37191007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mpox in people with past infection or a complete vaccination course: a global case series.
    Hazra A; Zucker J; Bell E; Flores J; Gordon L; Mitjà O; Suñer C; Lemaignen A; Jamard S; Nozza S; Nori AV; Pérez-Barragán E; Rodríguez-Aldama JC; Blanco JL; Delaugerre C; Turner D; Fuertes I; Leiro V; Walmsley SL; Orkin CM;
    Lancet Infect Dis; 2024 Jan; 24(1):57-64. PubMed ID: 37678309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.
    Bertran M; Andrews N; Davison C; Dugbazah B; Boateng J; Lunt R; Hardstaff J; Green M; Blomquist P; Turner C; Mohammed H; Cordery R; Mandal S; Campbell C; Ladhani SN; Ramsay M; Amirthalingam G; Bernal JL
    Lancet Infect Dis; 2023 Jul; 23(7):828-835. PubMed ID: 36924787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress and prospects on vaccine development against monkeypox infection.
    Saadh MJ; Ghadimkhani T; Soltani N; Abbassioun A; Daniel Cosme Pecho R; Taha A; Jwad Kazem T; Yasamineh S; Gholizadeh O
    Microb Pathog; 2023 Jul; 180():106156. PubMed ID: 37201635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
    Miller ER; McNeil MM; Moro PL; Duffy J; Su JR
    Vaccine; 2020 Nov; 38(47):7458-7463. PubMed ID: 33039207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse reactions following MPox (monkeypox) vaccination: An overview from the Dutch and global adverse event reporting systems.
    van der Boom M; van Hunsel F
    Br J Clin Pharmacol; 2023 Nov; 89(11):3302-3310. PubMed ID: 37344609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
    Varricchio F; Iskander J; Destefano F; Ball R; Pless R; Braun MM; Chen RT
    Pediatr Infect Dis J; 2004 Apr; 23(4):287-94. PubMed ID: 15071280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.
    Merad Y; Gaymard A; Cotte L; Perpoint T; Alfaiate D; Godinot M; Becker A; Cannesson O; Batalla AS; Oria-Yassir F; Landré S; Morfin F; Bouscambert M; Valour F; Ader F; Conrad A
    Euro Surveill; 2022 Dec; 27(50):. PubMed ID: 36695469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox - United States, May 22, 2022-January 31, 2023.
    Owens LE; Currie DW; Kramarow EA; Siddique S; Swanson M; Carter RJ; Kriss JL; Boersma PM; Lee FC; Spicknall I; Hurley E; Zlotorzynska M; Gundlapalli AV
    MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(13):342-347. PubMed ID: 36995962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mpox vaccination willingness, determinants, and communication needs in gay, bisexual, and other men who have sex with men, in the context of limited vaccine availability in the Netherlands (Dutch Mpox-survey).
    Dukers-Muijrers NHTM; Evers Y; Widdershoven V; Davidovich U; Adam PCG; Op de Coul ELM; Zantkuijl P; Matser A; Prins M; de Vries HJC; den Heijer C; Hoebe CJPA; Niekamp AM; Schneider F; Reyes-Urueña J; Croci R; D'Ambrosio A; van der Valk M; Posthouwer D; Ackens R; Ter Waarbeek H; Noori T; Hoornenborg E
    Front Public Health; 2022; 10():1058807. PubMed ID: 36684959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.